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THE EFFICACY OF H A L O F A N T R I N E IN T H E T R E A T M E N T 
OF A C U T E M A L A R I A IN N O N I M M U N E T R A V E L E R S 
T H O M A S WEINKE, T H O M A S LOSCHER, K L A U S FLEISCHER, H A R A L D 
K R E T S C H M E R , H A N S D. POHLE, B E R N D K O H L E R , T H O M A S S C H L U N K , R A L F 
CLEMENS, A N D H A N S L. B O C K 
U n i v e r s i t a t s k l i n i k u m R u d o l f V i r c h o w , I I M e d i z i n i s c h e K l i n i k , B e r l i n , G e r m a n y ; A b t e i l u n g für 
I n f e k t i o n s u n d T r o p e n m e d i z i n der Universität, München, G e r m a n y ; M i s s i o n s a r z t l i c h e K l i n i k , 
T r o p e n m e d i z i n , W u r z b u r g , G e r m a n y ; T r o p e n k l i n i k P a u l - L e c h l e r - K r a n k e n h a u s , T u b i n g e n , G e r m a n y ; 
S m i t h K l i n e Beecham, K l i n i s c h e F o r s c h u n g , München, G e r m a n y 
A b s t r a c t . A multicenter prospective trial was performed to investigate the efficacy and 
the tolerability of halofantrine in nonimmune patients with malaria imported from areas 
with drug-resistant falciparum parasites (mainly Africa). Forty-five of the 74 subjects were 
treated with a one-day regimen (3 x 500 mg) of halofantrine, and the other 29 received 
the same regimen with an additional treatment on day 7. In the second group, a 100% 
efficacy rate was demonstrated, but in the group receiving the one-day regimen, four 
recrudescences were observed in patients with falciparum malaria. Only five m i l d adverse 
reactions were seen, which disappeared spontaneously after the end of the treatment. We 
conclude that halofantrine is highly effective in curing malaria in nonimmune subjects. 
The treatment scheme for such persons should include an additional treatment on day 7 
for nonimmune individuals. This drug was well tolerated in our patients, indicating that 
halofantrine wi l l be useful in the treatment o f multidrug-resistant malaria in nonimmune 
persons. 
The spread of multi-resistant P l a s m o d i u m f a l -
c i p a r u m strains to many countries where malaria 
transmission occurs poses a considerable chal-
lenge in the treatment o f infected patients. 1 Fur-
thermore, severe side effects of other established 
antimalarial drugs such as pyrimethamine-sul-
fadoxine (Fansidar®) or amodiaquine restrict 
their use for Prophylaxis or treatment. 2 - 5 One of 
the newer drugs, mefloquine, has been shown to 
produce moderate to severe neuropsychiatric re-
actions with a frequency of 1 in 215 after ther-
apeutic use;6 reduced in vitro sensitivity has also 
been demonstrated with this drug. 7 Therefore, 
new drugs that are efficacious and safe are ur-
gently needed. 
Halofantrine, a phenanthrene methanol, is such 
a new antimalarial drug, and it has been shown 
to be efficacious i n semi-immune patients in var-
ious endemic a r ea s . 8 1 3 Data are scanty on non-
immune travelers who have contracted malaria 
during short term stays in the tropics and their 
treatment with halofantrine. 1 4 In semi-immune 
persons, a one-day treatment produced excellent 
results, but recrudescences were reported in 
nonimmune patients. 1 5 The current study was 
undertaken to investigate the efficacy and tol-
erability of halofantrine hydrochloride in non-
immune patients, and to evaluate the need for a 
regimen with a repetitive dose after one week. 
PATIENTS AND METHODS 
This multicenter trial was carried out pro-
spectively in four hospitals in Germany. Patients 
who returned from a stay in the tropics were 
screened and recruited i f they met the following 
criteria: 1) they had parasitologic evidence of 
parasites in the blood with clinical Symptoms of 
malaria, 2) they were older than 18 years of age 
and younger than 65 years of age, and 3) they 
were nonimmune white individuals l iv ing usu-
ally in Central Europe, or i f the patient is of 
African/Asian origin, they must have stayed more 
than one year outside endemic areas. Written 
informed consent for participation in the study 
was obtained from all patients. 
Parasite densities were calculated by counting 
asexual parasites against 5,000 red blood cells on 
Giemsa-stained thin blood films, or against 200 
white blood cells on thick blood films when the 
parasitemia was < 0.1%. 
Exclusion criteria were 1) severe or compl i -
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cated malaria (e.g., renal failure, severe Hypoten-
sion, central nervous System disorders, vomit ing, 
fever > 41°C) or a parasite count > 500,000/^1 
2) being pregnant or nursing, 3) body weight < 
40 kg, and 4) concomitant antimalarial treat-
ment. 
Forty-five patients were treated orally with 
halofantrine hydrochloride (3 x 500 mg tablets) 
within a 12-hr period (group 1). The other 29 
patients were given the same treatment regimen 
on day 0 and an additional treatment on day 7 
(group 2). N o differences could be observed be-
tween the two groups concerning travel desti-
nations. In those with P. vivax malaria, a Stan-
dard course of Primaquine was given after the 
treatment with halofantrine. Although 80 pa-
tients were enrolled in the study, six were not 
available for followup examinations, and a judg-
ment o f drug efficacy in these patients was not 
possible. The data from these six patients were 
included only in the evaluation of drug tolera-
bility. 
Efficacy and tolerability evaluations included 
hematologic examinations (hemoglobin level and 
white blood cell and platelet counts), clinical bio-
chemical tests (levels of Creatinine, blood urea 
nitrogen, bil irubin, liver transaminases and a l -
kaline Phosphatase, and serum electrolytes and 
glucose), urinalysis (glucose and protein levels), 
recording of body temperature, and parasite count 
(parasite density). Hematologic and biochemical 
values were determined on days 1-5, 7, 14, 21, 
and 28, urinalysis was performed once a week, 
and temperatures were recorded twice a day. Par-
asite counts were obtained before treatment, twice 
a day until blood smears were negative, and on 
days 5, 7, 14, 21, and 28. Cl in ica l investigations 
were carried out on days 1-5, 7, 14, 21, and 28. 
Thus, efficacy could be determined with the fol-
lowing parameters: eure rate, parasite clearance 
time (hr), fever clearance time (hr), and recru-
descence rate. Drug tolerability was measured by 
determination of the frequency and severity o f 
adverse reactions. 
RESULTS 
The 74 fully compliant subjects (55 men and 
19 women) had a mean age of 35.5 years (age 
ränge 23-61) and a mean body weight of 72.9 
kg (ränge 52-101.8). Sixty-two of the 74 patients 
(83.8%) were white and iived in Central Europe. 
Ten (13.5%) were of African origin and two (2.7%) 
were of Asian origin, but all had l ived in Ger-
many for a period o f more than one year. 
Plasmodium f a l c i p a r u m was detected in 50 pa-
tients and P. vivax in 20 patients; in four patients, 
the Plasmodium species could not be classified 
because of very low parasitemias and identifi-
cation of parasites on thick smears only. The 
mean pretreatment parasite count was 40, 350/ 
fA and the parasite density ranged from < 5,000/ 
Ml to 250,000/^1 (Table 1). The patients had con-
tracted their malaria infections in sub-Saharan 
Africa (78%), South America (6%), the Indian 
subcontinent (6%), and southeast As ia (10%). 
Malar ia chemoprophylaxis was used by 37 (50%) 
of the 74 travelers, and consisted mainly of chlo-
roquine (n = 21) or chloroquine plus proguanil 
(n = 9); 37 (50%) patients d id not use any che-
moprophylactic agent. 
Pretreatment clinical Symptoms consisted o f 
fever (n = 71, 95.9%), headache (n = 64, 87%), 
dizziness (n = 50, 68%), chills/rigors (n = 38, 
51%), nausea (n = 45, 61%), diarrhea (n = 8, 
11%), and abdominal pain (n = 13, 18%). The 
median fever clearance time was 53 hr (ränge 4 -
185) and was shorter than the parasite clearance 
time of 65 hr (ränge 18-225). Clearance times 
were slightly longer in those with P. f a l c i p a r u m 
infections (fever clearance time = 49 hr and par-
asite clearance time = 66 hr) compared with those 
with P. vivax infections (42 and 62.5 hr, respec-
tively), but these differences were not statistically 
significant. 
In all patients, clinical Symptoms of malaria 
disappeared and parasites could no longer be de-
tected on day 14 (Table 2). Subsequently, four 
infections recrudesced in group 1 (treatment on 
day 0 only) on days 14, 22 (two patients), and 
28, respectively, indicating that four (15.4%) o f 
26 patients in group 1 with P. f a l c i p a r u m infec-
tions recrudesced. In group 2 (treatment on days 
0 and 7), none of the 24 patients with P. f a l c i p -
a r u m malaria recrudesced. Although this differ-
ence was not statistically significant, a clinically 
relevant trend was apparent. The four patients 
whose infections recrudesced were white ind i -
viduals; three o f them had used a chemopro-
phylactic (chloroquine), while the fourth patient 
had not used any chemoprophylactic. Their body 
weights d id not differ significantly from the suc-
cessfully treated group, and their ini t ial parasite 
counts were only slightly lower (3,500, 9,500, 
10,500, and 48,000/jui, respectively). A l l four pa-
tients had returned from tropical Africa. A def-
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T A B L E 1 
P a r a s i t e m i a i n the 74 m a l a r i a patients i n t h i s study 
Parasites/Ml No. (%) 
< 5,000 9(12.2) 
5,000-50,000 48 (64.9) 
50,000-100,000 8(10.8) 
100,000-250,000 2 (2.7) 
>250,000 3(4.1) 
Not done 4 (5.4) 
Total 74(100.0) 
inite eure o f these recrudescences was possible 
by treatment with quinine or mefloquine. N o 
recrudescences were observed in any patients i n 
both groups with P . v i v a x malaria. 
Cl in ica l tolerance to treatment with halofan-
trine was good, with only six patients reporting 
side effects. One patient each complained of d i -
arrhea, itching, nausea, skin rash, fever, and an-
gioneurotic (Quincke) edema. A l l reactions were 
graded as m i l d and disappeared spontaneously a 
few days after the end of the halofantrine treat-
ment. F ive of these six adverse reactions were 
confined to those who had a one-day therapy 
regimen. Only angioneurotic edema occurred in 
a patient who reeeived two days of therapy; con-
comitant to falciparum malaria, the same patient 
had Dengue fever. Treatment of this patient with 
a second dose of halofantrine on day 7 d id not 
produce any adverse reaction. Therefore, it is 
more likely that the angioneurotic (Quincke) ede-
ma was a reaction that occurred after the onset 
of Dengue fever. Thus, five (6.25%) of 80 patients 
developed mi ld , reversible side effects. Hema-
tologic and clinical biochemical test results re-
mained within the normal limits after treatment 
in a l l patients. 
In addition, two patients developed neurologic 
Symptoms within the 28-day followup period that 
were judged to be unrelated to the intake of hal-
ofantrine. A 32-year-old woman who reeeived 
halofantrine on day 0 complained o f weakness 
in her legs on day 19 post-treatment. She was 
hospitalized and diagnosed as having Gui l l a in -
Barre Syndrome (with typical cerebrospinal fluid 
findings) of unknown etiology. A 50-year-old man 
who reeeived halofantrine on days 0 and 7 de-
veloped viral encephalitis with disorientation and 
speech disturbance 23 days after initiating treat-
ment. H e had a significant influenza A virus titer, 
indicating that influenza A virus was the prob-
able cause of his encephalitis. Both patients i m -
proved spontaneously. 
DISCUSSION 
The role of antimalarial drugs in the control 
of malaria has undergone major revisions in re-
cent years with the increase o f drug resistance in 
P l a s m o d i u m f a l c i p a r u m . Thir ty years ago, the 
sensitivity of the parasite was the norm. Today, 
resistance to chloroquine and other alternative 
Compounds is dominant and still spreading.1 This 
has encouraged the development of new drugs. 
The Walter Reed A r m y Institute of Research has 
identified various new antimalarial drugs, i n -
cluding halofantrine in the 1970s. 1 6 1 7 This Com-
pound, a phenanthrene methanol, proved to be 
more efficacious and less toxic than other new 
Compounds, and has undergone extensive eval-
uation since that t ime. 1 6 1 8 It has proved to be 
effective in the treatment of drug-resistant strains 
of P . f a l c i p a r u m in semi-immune patients in var-
ious geographic loca l i t i es . 8 - 1 3 
In this study, we show that halofantrine is 100% 
effective in the treatment o f malaria in nonim-
mune patients i f a regimen including a second 
treatment on day 7 is applied. A similar expe-
rience was reported by Bernard and others, 1 4 who 
successfully treated 59 patients from tropical Af -
rica with a two-day course o f halofantrine on 
days 1 and 8. The one-day dosing regimen (3 x 
500 mg in group 1) in our study seems to be less 
effective, since four (15.4%) of 26 patients with 
P . f a l c i p a r u m infections recrudesced. Our results 
T A B L E 2 
P a r a s i t e c l e a r a n c e a n d recovery f r o m fever i n the 74 m a l a r i a patients 
Day 
Ö 2 5 7 \Ä~ 
No. (%) of parasitemic patients 74 (100) 56 (76) 2 (3) 1 (1) 0 (0) 
Median parasitemia (parasites//d) 40,350 2,000 0 0 0 
Parasite density/Ml (ränge) 50-500,000 50-20,000 < 50-2,250 <50 0 
No. (%) of patients with fever (>38°C) 71 (96) 25 (34) 3 (4) 1 (1) 0 (0) 
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indicate that the one-day dosing regimen, which 
is extremely effective in semi-immune persons, 
is not sufficient in nonimmune travelers. Thus, 
the manufacturer of halofantrine (Smith K l i n e 
Beecham, M ü n c h e n , Germany) has taken this 
into consideration and recommends an adult 
equivalent dose o f 3 x 500 mg on days 0 and 7. 
Because of the relatively late recrudescences (days 
14, 22, and 28) seen in four patients following 
treatment with halofantrine, it is essential to fol-
low-up patients for at least one month before a 
eure may be confirmed. In the interest of the 
nonimmune patient, a treatment on day 0 only 
can no longer can be justified. These findings 
confirm the preliminary data of Coulaud and 
omers, 1 5 who observed three recrudescences in 
11 nonimmune individuals and recommended a 
second treatment on day 14. Since attempts to 
use a Single dose regimen were unsuccessful, 1 9 we 
chose the three-dose regimen used in this study. 
In general, halofantrine was well tolerated by 
our patients. We saw no significant effects on 
hematologic or biochemical Parameters, and the 
few m i l d reactions observed disappeared spon-
taneously. A judgment about the frequency of 
rare severe drug reactions in the order o f 1/1,000 
or less is usually made only after the drug has 
been licensed for a few years, as shown by the 
experience wi th pyr imethamine-sul fadoxine 
(Fans ida r®) 2 or mefloquine. 6 - 2 0 - 2 1 Therefore, a 
definitive Statement concerning rare side effects 
after treatment with halofantrine cannot be made, 
but in view of its relatively short half-life of 1-2 
days , 2 2 - 2 3 (compared with 25 days for meflo-
quine), long-lasting side effects are not very prob-
able. Another advantage of its short half-life is 
that this can be of importance in reducing the 
selection of less susceptible parasites, thereby de-
laying the emergence o f halofantrine resistance. 
(In this regard, halofantrine wi l l not be used for 
general chemoprophylaxis, but only as a treat-
ment drug.) 
One problem encountered in using halofan-
trine is that it is poorly soluble in water, which 
probably explains the wide Variation i n bio-
availability i n different subjects. 2 2 This may also 
aecount for the recrudescences we observed, a l -
though we d id not measure drug levels in the 
sera of our patients. It was possible to exclude 
reinfection in our patients, since all of them stayed 
in Germany during the followup period. The rec-
ommendation that patients should take halofan-
trine with a fatty meal to increase absorption is 
of l imi ted practicability, since patients with cl in-
ical signs o f malaria usually do not like to eat 
fatty food. Since no intravenous formulation of 
this drug currently exists, this drug has been re-
stricted for use only in mild-to-moderate malaria 
cases. 
H a l f o f our patients took a chemoprophylaxis 
with chloroquine, and most of these cases orig-
inated from sub-Saharan Africa, where chloro-
quine resistance is well established. 1 Our findings 
indicate that halofantrine is effective in the treat-
ment o f chloroquine-resistant P . f a l c i p a r u m ma-
laria, as well as in P . v i v a x infections in non-
immune subjects. G iven the finding that this drug 
was both efncacious and well-tolerated, its role 
i n the treatment o f multidrug-resistant falcipa-
rum malaria appears promising. 
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